Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 2
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 4
2019 2
2020 3
2021 6
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL, Kappos L, Bar-Or A, Wiendl H, Paling D, Williams M, Gold R, Chan A, Milo R, Das Gupta A, Karlsson G, Sullivan R, Graham G, Merschhemke M, Häring DA, Vermersch P. Hauser SL, et al. Among authors: paling d. Neurol Ther. 2023 Oct;12(5):1491-1515. doi: 10.1007/s40120-023-00518-0. Epub 2023 Jul 14. Neurol Ther. 2023. PMID: 37450172 Free PMC article. Review.
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis.
Kramer J, Linker R, Paling D, Czaplinski A, Hoffmann O, Yong VW, Barker N, Ross AP, Lucassen E, Gufran M, Hu X, Zielman R, Seifer G, Vermersch P. Kramer J, et al. Among authors: paling d. Mult Scler J Exp Transl Clin. 2023 Oct 10;9(4):20552173231203816. doi: 10.1177/20552173231203816. eCollection 2023 Oct-Dec. Mult Scler J Exp Transl Clin. 2023. PMID: 37829441 Free PMC article.
Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C, Bursnall M, Ciccarelli O, Coles AJ, Cooper C, Giovannoni G, Gabriel I, Kazmi M, Kyriakou C, Nicholas R, Paling D, Peniket A, Scolding N, Silber E, de Silva T, Venneri A, Walters SJ, Young C, Muraro PA, Sharrack B, Snowden JA; StarMS trial team. Brittain G, et al. Among authors: paling d. BMJ Open. 2024 Feb 5;14(2):e083582. doi: 10.1136/bmjopen-2023-083582. BMJ Open. 2024. PMID: 38316583 Free PMC article.
Measuring coping in multiple sclerosis: The Coping Index-MS.
Young CA, Mills RJ, Langdon D, Rog DJ, Sharrack B, Kalra S, Majeed T, Footit D, Harrower T, Nicholas RS, Ford HL, Woolmore J, Johnstone C, Thorpe J, Paling D, Ellis C, Hanneman CO, Tennant A. Young CA, et al. Among authors: paling d. Mult Scler. 2022 Dec;28(14):2274-2284. doi: 10.1177/13524585221114004. Epub 2022 Aug 24. Mult Scler. 2022. PMID: 36000480
Optic neuritis as presenting primary hypoparathyroidism.
Arshad MF, Karim R, Paling D, Jayamanne G. Arshad MF, et al. Among authors: paling d. BMJ Case Rep. 2018 Nov 28;11(1):e227032. doi: 10.1136/bcr-2018-227032. BMJ Case Rep. 2018. PMID: 30567123 Free PMC article.
Fatigue in multiple sclerosis: A UK MS-register based study.
Moore H, Nair KPS, Baster K, Middleton R, Paling D, Sharrack B. Moore H, et al. Among authors: paling d. Mult Scler Relat Disord. 2022 Aug;64:103954. doi: 10.1016/j.msard.2022.103954. Epub 2022 Jun 7. Mult Scler Relat Disord. 2022. PMID: 35716477 Free article.
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
Young CA, Mills R, Langdon D, Sharrack B, Majeed T, Kalra S, Footitt D, Rog D, Harrower T, Nicholas R, Woolmore J, Thorpe J, Hanemann CO, Ford H, Paling D, Ellis C, Palace J, Constantinescu C, Tennant A. Young CA, et al. Among authors: paling d. J Neurol Sci. 2022 May 15;436:120188. doi: 10.1016/j.jns.2022.120188. Epub 2022 Feb 18. J Neurol Sci. 2022. PMID: 35303502
33 results